LEADER 01018nam0-2200313---450- 001 990009917020403321 005 20141117102131.0 035 $a000991702 035 $aFED01000991702 035 $a(Aleph)000991702FED01 035 $a000991702 100 $a20141117d2006----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa---ac--001yy 200 1 $a<>costruzione del regime$eurbanistica, architettura e politica nell'Abruzzo del fascismo$fRaffaele Giannantonio$gpresentazione di Luciano Patetta$gcontributi di Enzo Fimiani ... [et al.] 210 $aLanciano$cCasa editrice Rocco Carabba$d2006 215 $a859 p.$cill.$d29 cm 225 1 $aStoria e documenti$v12 700 1$aGiannantonio,$bRaffaele$0521882 702 1$aPatetta,$bLuciano$f<1935- > 702 1$aFimiani,$bEnzo 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990009917020403321 952 $a10.1279$bs.i.$fDARST 959 $aDARST 996 $aCostruzione del regime$9831415 997 $aUNINA LEADER 03498nam 2200589Ia 450 001 9910144093303321 005 20180702173038.0 010 $a1-281-84052-1 010 $a9786611840525 010 $a0-470-69740-7 010 $a0-470-69741-5 035 $a(CKB)1000000000551489 035 $a(EBL)366846 035 $a(OCoLC)437234437 035 $a(SSID)ssj0000136162 035 $a(PQKBManifestationID)11150469 035 $a(PQKBTitleCode)TC0000136162 035 $a(PQKBWorkID)10064010 035 $a(PQKB)11282680 035 $a(MiAaPQ)EBC366846 035 $a(EXLCZ)991000000000551489 100 $a20080305d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDefining optimal immunotherapies for type 1 diabetes$b[electronic resource] /$f[editors: Gregory Bock and Jamie Goode] 210 $aLondon $cNovartis Foundation$d2008 215 $a1 online resource (224 p.) 225 1 $aNovartis Foundation symposium ;$vv. 292 300 $aDescription based upon print version of record. 311 $a0-470-72325-4 320 $aIncludes bibliographical references and index. 327 $aDefining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes 327 $aCD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index 330 $aThis book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials.The book integrates information from human and animal studies.The book considers T1D within the broader context of autoimmune disease.The format contains several discussions, which address specific questions and provides 410 0$aNovartis Foundation symposium ;$vv. 292. 606 $aDiabetes$xImmunotherapy$vCongresses 606 $aDiabetes$xTreatment$vCongresses 608 $aElectronic books. 615 0$aDiabetes$xImmunotherapy 615 0$aDiabetes$xTreatment 676 $a616.46206 712 02$aNovartis Foundation. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144093303321 996 $aDefining optimal immunotherapies for type 1 diabetes$92186506 997 $aUNINA